Conservancy workers being forced into manual scavenging in Thane hospital: Labour union
These workers, who number more than a hundred, have also been denied basic wages, safety equipment and mandated health facilities by the Pune-based contracting firm that has deployed them, claimed Sharmik Janata Sangh general secretary Jagdish Khairalia.
"These safai karamcharis are cleaning excreta with their bare hands. This is not only illegal but also inhumane. Despite working there since 2008, they have not been paid salaries in time. Uniforms have been distributed only once in six years, and the workers have never been provided with protective gear or safety equipment while handling biohazardous waste," he told reporters.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
2 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
NDTV
2 hours ago
- NDTV
Woman Denied Boarding At Miami Airport Due To Cosmetic Procedure, Airline Responds
A woman claimed that she was denied boarding by Spirit Airlines at Miami International Airport Wednesday afternoon because of concerns over a cosmetic procedure she underwent days earlier. The Houston-based woman, named Shataria Banks, captured a video of her confrontation at the Spirit Airlines desk at the airport. "Even though y'all have my medical clearance, even though my doctor's-y'all are still restricting me to fly," Banks is heard saying in the video. While speaking to CBS News, she said she had arrived in Miami from Houston last week for a cosmetic procedure. She didn't reveal details about the procedure and preferred to keep it private. She came to the airport with documentation from her doctor clearing her to fly after several days of recovery. However, she was told that she would not be allowed to board when she tried to check in. "Well, we don't have it in writing-verbatim-from their spirit supervisor. It was just how I was treated on top of them just neglecting what my doctor said," Banks said, describing the exchange with Spirit employees. Here's what the airline said: "The safety and well-being of our Guests is our top priority. Our records show the agents followed our procedures and consulted with a designated on-call medical professional via our vendor MedLink to verify the Guest's fitness to travel," Spirit Airlines said in a statement. "The medical professional at MedLink was informed of the Guest's documentation and advised that the Guest was not fit to travel based on their condition at the time and in the interest of their safety. The Guest was ultimately issued a refund for the flight." As per the report, Banks said that she understands the need for safety; however, she called for clearer protocols. "I'm not saying that they can't deny their travelers and they're looking out for their safety, but have something in place, because everybody don't have money to waste for a new flight. I never want to fly with them, ever, ever," she said. The airline paid her the refund.
